|1.||Comstock, Timothy L: 13 articles (05/2015 - 03/2009)|
|2.||Morris, Timothy W: 12 articles (05/2015 - 05/2009)|
|3.||Paterno, Michael R: 8 articles (01/2011 - 03/2009)|
|4.||Gearinger, Lynne S: 7 articles (12/2013 - 01/2011)|
|5.||Usner, Dale W: 7 articles (01/2011 - 03/2009)|
|6.||Haas, Wolfgang: 6 articles (05/2012 - 05/2009)|
|7.||Lichtenstein, Steven J: 6 articles (03/2012 - 03/2003)|
|8.||Ali, Asgar: 5 articles (05/2006 - 02/2003)|
|9.||Decory, Heleen H: 4 articles (01/2012 - 01/2010)|
|10.||Stroman, David: 4 articles (07/2011 - 01/2006)|
|1.||7- ((3R)- aminohexahydro- 1H- azepin- 1- yl)- 8- chloro- 1- cyclopropyl- 6- fluoro- 1,4- dihydro- 4- oxo- 3- quinolinecarboxylic acidIBA
10/01/2010 - "Taken together, these nonclinical data indicate that besifloxacin has a favorable ocular PK/PD profile, consistent with the reported clinical efficacy of besifloxacin in the treatment of bacterial conjunctivitis, and consistent with the profile needed for ocular surface sterilization."
05/01/2012 - "Treatment with besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days was effective and safe in adults and children with bacterial conjunctivitis. "
05/01/2012 - "Besifloxacin ophthalmic suspension 0.6% given thrice daily for 5 days is safe and effective in the treatment of patients with bacterial conjunctivitis. "
04/01/2010 - "Besifloxacin ophthalmic suspension 0.6% was shown to be safe and effective for the treatment of bacterial conjunctivitis in children and adolescents aged 1-17 years."
06/01/2015 - "This review provides an up-to-date summary of studies on causative pathogens in acute bacterial conjunctivitis; recent geographic trends in bacterial resistance among ocular pathogens, including that of methicillin-resistant Staphylococcus aureus; the efficacy of besifloxacin in preclinical and clinical studies; its safety; and the role of besifloxacin in combating resistant strains. "
|2.||Ophthalmic Solutions (Eye Drops)IBA
02/01/2011 - "A better improvement in artificially induced bacterial conjunctivitis in rats' cornea was observed with the developed formulae; thus it can be considered as a viable alternative to conventional eye drops."
07/01/2011 - "To evaluate the comparative efficacy of Ayurvedic formulation a Rasanjana Madhu (RM) eye drops and Honey Rose (HR) water eye drops in Netra Abhishyanda in mucopurulent conjunctivitis, the current study is planned. "
01/01/2012 - "Although acute bacterial conjunctivitis is frequently self limiting, the findings from this updated systematic review suggest that the use of antibiotic eye drops is associated with modestly improved rates of clinical and microbiological remission in comparison to the use of placebo. "
05/01/2006 - "The developed formulation was compared with marketed eye drops in efficacy of treatment of bacterial conjunctivitis that was induced artificially in rabbits. "
06/01/2007 - "Bacterial conjunctivitis in children: antibiotic eye drops only if eye washing is ineffective."
|3.||moxifloxacin (Avelox)FDA Link
07/01/2011 - "Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis."
01/01/2011 - "The efficacy of moxifloxacin 0.5% ophthalmic solution in the treatment of bacterial conjunctivitis has been shown in three randomized, double-blind, multicentre trials. "
04/01/2010 - "[Efficacy of moxifloxacin in treating bacterial conjunctivitis: a meta-analysis]."
01/01/2011 - "Clinical microbiological eradication data from three randomized, double-masked, parallel group studies of patients with bacterial conjunctivitis (two vehicle controlled; one active controlled with moxifloxacin ophthalmic solution, 0.5%) were integrated. "
01/01/2010 - "Data were drawn from two phase I safety studies in healthy adults, an open-label, phase II pharmacokinetic study of patients with bacterial conjunctivitis and from integrated data from three randomized, double-masked, parallel-group, safety and efficacy studies of patients with bacterial conjunctivitis (two were vehicle controlled and one was active controlled with moxifloxacin ophthalmic solution 0.5%, as base). "
|4.||Anti-Bacterial Agents (Antibiotics)IBA
01/01/2006 - "Acute bacterial conjunctivitis is frequently a self-limiting condition, but the use of antibiotics is associated with significantly improved rates of clinical and microbiological remission."
06/01/2001 - "Acute bacterial conjunctivitis is frequently a self-limiting condition but the use of antibiotics is associated with significantly improved rates of early clinical remission, and early and late microbiological remission. "
01/01/2000 - "Acute bacterial conjunctivitis is frequently a self-limiting condition but the use of antibiotics is associated with significantly improved rates of early clinical remission and early and late microbiological remission. "
09/01/2001 - "Are topical antibiotics effective in treating bacterial conjunctivitis?"
01/01/2002 - "Review: antibiotics modestly increase remission rates in acute bacterial conjunctivitis."
|5.||Tobramycin (Nebcin)FDA LinkGeneric
09/01/2005 - "To compare the safety and efficacy of a new enhanced viscosity ophthalmic formulation of tobramycin, given twice daily (BID), with the existing four times daily (QID) treatment regimen in patients with acute bacterial conjunctivitis. "
01/01/2010 - "influenzae in vitro faster than tobramycin and gentamicin, suggesting its potential clinical benefit as a first-line treatment for bacterial conjunctivitis to minimize patient symptoms and to limit the contagiousness of the disease."
11/01/2008 - "Antibacterial efficacy of topically applied azithromycin 1.5% was compared with tobramycin 0.3% in a multicenter, randomized, investigator-masked study for the treatment of purulent bacterial conjunctivitis. "
06/01/2007 - "The study was designed to evaluate the efficacy of an ophthalmic formulation of 1% azithromycin in DuraSite((R)) (AzaSite, InSite Vision, Alameda CA, USA) and demonstrate equivalence with 0.3% tobramycin ophthalmic solution, USP, for the treatment of bacterial conjunctivitis as defined by the resolution of clinical signs and the eradication of pathogens. "
02/12/2012 - "Azithromycin 1.5% ophthalmic solution for 3 days (1 drop twice daily) was noninferior to tobramycin 0.3% ophthalmic solution for 7 days (1 drop every 2 hours) in paediatric and adult patients with purulent bacterial conjunctivitis, with regard to clinical cure and bacteriological resolution on day 9, in a randomized, investigator-masked, multicentre study. "
|6.||Ofloxacin (Levofloxacin)FDA LinkGeneric
10/01/2003 - "After 5 days of therapy, 0.5% levofloxacin ophthalmic solution was found to be safe and effective in treating pediatric bacterial conjunctivitis. "
08/01/2003 - "Levofloxacin 0.5% ophthalmic solution is safe and effective for treatment of bacterial conjunctivitis."
01/01/2009 - "Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis."
08/01/2003 - "In this prospective, randomised, placebo controlled, double masked, multicentre study, 249 patients with bacterial conjunctivitis received either 0.5% levofloxacin (n = 126) or placebo (n = 123) for 5 days, administered every 2 hours on days 1-2, then every 4 hours on days 3-5. Cultures were obtained and signs/symptoms evaluated at baseline, interim, and final visits. "
10/01/2003 - "To compare the efficacy and safety of 0.5% levofloxacin ophthalmic solution (Quixin; Santen, Napa, CA) with 0.3% ofloxacin (Ocuflox; Allergan Inc., Irvine, CA) and placebo for the treatment of pediatric bacterial conjunctivitis. "
|7.||Azithromycin (Zithromax)FDA LinkGeneric
01/01/2010 - "We found six reports of randomized controlled trials investigating the role of azithromycin 1% in DuraSite((R)) for the management of acute bacterial conjunctivitis. "
01/01/2015 - "The azithromycin 1.5% regimen produced a rapid resolution of cardinal signs of purulent bacterial conjunctivitis with a more convenient dosage regimen. "
01/01/2012 - "AzaSite(®) (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis. "
01/01/2010 - "Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis."
06/01/2009 - "The pharmacokinetics of a 2% ocular solution of azithromycin in DuraSite was evaluated in rabbits to determine whether the PK/PD parameters support a once-a-day for three-day therapeutic regimen against bacterial conjunctivitis. "
|8.||Ciprofloxacin (Cipro)FDA LinkGeneric
01/01/2003 - "The main subject of the study was to evaluate efficacy of ciprofloxacin 0.3% ophthalmic solution (Ciloxan) in the treatment of bacterial conjunctivitis and surgical prophylaxis. "
08/01/1997 - "This study showed that topically applied ciprofloxacin ophthalmic solution is safe and effective in a pediatric population experiencing acute bacterial conjunctivitis."
08/01/1997 - "Topically applied ciprofloxacin (3 mg/mL) is known to be a safe and effective treatment for adults suffering from bacterial conjunctivitis; however, the safety and effectiveness of this broad-spectrum fluoroquinolone in pediatric patients is not well established. "
08/01/1997 - "A study was conducted to determine the safety and efficacy of topically applied ciprofloxacin ophthalmic solution in a pediatric population experiencing acute bacterial conjunctivitis. "
04/01/2004 - "The reported therapeutic success rate (95%) and bacteriological analysis confirmed the effectiveness of ciprofloxacin in subjects with bacterial conjunctivitis and bacterial blepharoconjunctivitis. "
|9.||Fusidic Acid (Fucithalmic)IBA
08/01/1995 - "Topical fusidic acid may not be optimal empiric therapy of bacterial conjunctivitis."
08/01/1999 - "Topical fusidic acid gel is also effective in bacterial conjunctivitis and other minor external eye infections, and may be effective in reducing bacterial flora in the conjunctival sac prior to eye surgery. "
06/01/2002 - "The clinical and bacteriologic efficacy of fusidic acid viscous drops combined with the convenience of a twice-daily dosage regimen establishes this antibiotic as first-line treatment for suspected acute bacterial conjunctivitis and a favourable alternative to other broad-spectrum antibiotics."
06/01/2002 - "The authors compared the clinical and microbiologic efficacy, safety and acceptability of 1% fusidic acid viscous drops (Fucithalmic) with 0.3% tobramycin ophthalmic solution (Tobrex) in the treatment of suspected bacterial conjunctivitis. "
06/01/2002 - "Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops."
|10.||Chloramphenicol (Chloromycetin)FDA Link
04/01/2015 - "Down-scheduling of ophthalmic chloramphenicol has improved pharmacists' capability to treat acute bacterial conjunctivitis, largely as a replacement for products previously available OTC, rather than fewer general practitioner consultations. "
04/01/2015 - "An evaluation of the reclassification of ophthalmic chloramphenicol for the management of acute bacterial conjunctivitis in community pharmacies in Western Australia."
01/01/1998 - "191 patients (lomefloxacin 96, chloramphenicol 95) were enrolled in this study with clinically diagnosed acute bacterial conjunctivitis. "
01/01/1998 - "We performed a prospective, randomised, investigator-masked and parallel-group study to compare topical lomefloxacin 0.3% instilled twice daily with topical chloramphenicol instilled five times daily in the treatment of acute bacterial conjunctivitis. "
04/01/2002 - "Treatment of acute neonatal bacterial conjunctivitis: a comparison of fucidic acid to chloramphenicol eye drops."
|1.||Refractive Surgical Procedures
|2.||Ambulatory Care (Outpatient Care)
12/01/2005 - "Uncertainty remains about the extent to which findings from our previously published systematic review and meta-analysis of double-blind, randomised controlled trials of topical antibiotics compared with placebo in the management of patients with acute bacterial conjunctivitis treated in secondary care outpatient settings are generalisable to the management of the condition in primary care settings. "
|3.||Hydrophilic Contact Lenses (Hydrophilic Contact Lens)
10/01/2005 - "aureus in acute bacterial conjunctivitis in soft contact lens wearers."
01/01/2001 - "The most common pathologies seen were soft contact lens complications, non-contact lens corneal pathology, conjunctivitis (bacterial, viral, and adenoviral), and ocular trauma (foreign bodies, chemical splashes, blunt injury). "
|5.||Home Nursing (Nursing, Home)
05/01/2011 - "In the absence of national HAI definitions applicable to the nursing home setting, we used modified definitions based on US Centers for Disease Control and Prevention criteria for bloodstream infection, lower respiratory tract infection, bacterial conjunctivitis, and gastroenteritis. "